Cryoport has entered an agreement to support TiGenix’s Phase Ib/IIa clinical trial to investigate the safety and efficacy of Cx611 to treat sepsis in adults with severe community‐acquired bacterial pneumonia.

Cx611 is a donor-derived stem cell platform that aims to develop a new treatment for sepsis.

Under the latest agreement, Cryoport will provide global logistics support for transporting cryogenically preserved clinical commodities to TiGenix.

Using Cryoport solutions, TiGenix will be able to constantly monitor its shipments and track the conditions and location of its stem cells while in transit.

The arrangement is also expected to smoothly conduct TiGenix’s new randomised double-blind placebo-controlled SEPCELL trial that expects to enrol 180 patients at up to 50 centres.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The emergence of increasingly drug-resistant bacteria, alongside ageing populations around the world, is driving a growing number of sepsis cases.”

Cryoport CEO Jerrell Shelton said: “Sepsis is a potentially life-threatening complication of infection, which can lead to systemic inflammation and, in the worst cases, organ failure.

“The emergence of increasingly drug-resistant bacteria, alongside ageing populations around the world, is driving a growing number of sepsis cases.

“TiGenix aims to leverage the anti-inflammatory properties found in stem cells to develop a novel treatment for sepsis, using its allogeneic (donor derived) stem cell platform, Cx611.”

Currently, Cryoport provides its solutions to points-of-care, central laboratories, pharmaceutical companies, manufacturers, university researchers, and others.

The company’s current range of temperature controlled logistics solutions includes Cryoport Express shippers, SmartPak II condition monitoring system, Cryoportal logistics management platform, among others.